Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study Evaluating the Safety, Tolerability, and Efficacy of Stereotactic Intracerebral Transplantation of Human Allogeneic Induced Pluripotent Stem Cell-derived Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).

NCT07617012 is registered in ClinicalTrials.gov with XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07617012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study Evaluating the Safety, Tolerability, and Efficacy of Stereotactic Intracerebral Transplantation of Human Allogeneic Induced Pluripotent Stem Cell-derived Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
Lead sponsor
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 15, 2026
Completion date
June 30, 2028
Enrollment
3 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

the treatment of multiple system atrophy parkinsonian variant (msa-p)